Online citations, reference lists, and bibliographies.
← Back to Search

Scientific Advances And New Frontiers In Mesothelioma Therapeutics.

L. Mutti, T. Peikert, B. Robinson, A. Scherpereel, A. Tsao, M. D. de Perrot, G. Woodard, D. Jablons, Jacinta R. Wiens, F. Hirsch, H. Yang, M. Carbone, A. Thomas, R. Hassan
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.
This paper references
Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.
K. Uematsu (2007)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1038/sj.onc.1208180
Malignant Mesothelioma as both a challenge and an opportunity
L. Mutti (2004)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1289/EHP.97105S51257
Pleural macrophage recruitment and activation in asbestos-induced pleural injury.
N. Choe (1997)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1164/rccm.201103-0554CR
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
D. Sterman (2011)
10.6004/JNCCN.2016.0087
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/j.ijrobp.2015.06.029
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
E. Minatel (2015)
10.1158/1078-0432.CCR-15-2133
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1016/B978-0-12-382227-7.00022-7
Validation of Candidate Protein Biomarkers
Maria P. Pavlou (2013)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.18632/genesandcancer.124
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
Noushin Nabavi (2016)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1158/0008-5472.CAN-14-0337
Discovery of mesothelin and exploiting it as a target for immunotherapy.
I. Pastan (2014)
10.1186/1471-2407-13-22
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
R. Federico (2012)
10.1158/1078-0432.CCR-11-1808
Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation
B. Burt (2012)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1200/JCO.2013.31.15_SUPPL.7528
A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): Clinical results of a single-center trial.
W. Buikhuisen (2013)
10.1164/rccm.201508-1573OC
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1165/rcmb.2010-0026RT
Gene therapy for mesothelioma and lung cancer.
A. Vachani (2010)
10.1186/1471-2407-14-304
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
L. Cortes-Dericks (2013)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1016/j.jtho.2017.05.021
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
A. Tsao (2017)
10.1016/J.EJCTS.2006.01.015
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2006)
10.1073/pnas.0604008103
TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis
H. Yang (2006)
10.1183/09059180.00007014
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
O. D. Røe (2015)
10.3892/IJMM.11.2.161
Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone.
M. T. Valle (2003)
10.1016/J.JTHO.2016.11.300
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
J. Quispel-Janssen (2017)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1080/2162402X.2015.1011492
Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
J. Creaney (2015)
10.1038/nrc3792
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier (2014)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1158/1535-7163.MCT-15-0583
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Mayura Meerang (2016)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1073/pnas.1105887108
Erionite exposure in North Dakota and Turkish villages with mesothelioma
M. Carbone (2011)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J
Simian virus 40 and human tumors: It is time to study mechanisms
M. Carbone (1999)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.tcb.2012.04.006
The Hippo signaling pathway and stem cell biology.
A. Ramos (2012)
10.1038/nature06835
Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling
Ilaria Malanchi (2008)
10.1158/0008-5472.CAN-11-3481
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.
S. Jube (2012)
10.1097/JTO.0000000000000506
The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada
F. Baumann (2015)
10.1200/JCO.2016.68.3672
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
R. Hassan (2016)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.3816/CLC.2003.N.031
Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.
A. Gazdar (2003)
10.21037/jtd.2017.10.16
Surgery for malignant pleural mesothelioma: an international guidelines review.
S. Ricciardi (2018)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1982)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1200/JCO.2016.71.2109
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
A. Tan (2017)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1097/JTO.0000000000000493
Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing
A. Miyanaga (2015)
10.1002/ijc.11710
Preclinical evaluation of the nonsteroidal anti‐inflammatory agent celecoxib on malignant mesothelioma chemoprevention
A. Catalano (2004)
10.3978/j.issn.2218-6751.2014.07.01
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
10.1053/j.semtcvs.2014.08.003
Novel induction therapies for pleural mesothelioma.
L. Donahoe (2014)
10.1016/j.clgc.2015.05.009
Malignant Mesothelioma of the Tunica Vaginalis: A Rare Neoplasm--Case Report and Literature Review.
M. Segura-González (2015)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1073/pnas.0808816106
Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice
D. Altomare (2009)
10.1007/s00408-015-9744-4
Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells
M. Acencio (2015)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1038/bjc.2015.481
Oncolytic viruses: finally delivering
L. Seymour (2016)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
10.1038/cdd.2017.95
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1158/1078-0432.CCR-05-0405
Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy
D. Sterman (2005)
10.1016/J.LUNGCAN.2005.03.015
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
10.1371/journal.pone.0057346
Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma
H. Li (2013)
10.1158/1078-0432.CCR-11-2259
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
M. Carbone (2011)
10.1289/EHP.94102S10107
Oxygen radicals and asbestos-mediated disease.
T. Quinlan (1994)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1126/science.1156995
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Catherine Dostert (2008)
10.1016/S1470-2045(16)00024-3
Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
A. Rimner (2016)
10.1177/107327480601300402
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2014.58.3377
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
R. Andtbacka (2015)
10.1111/j.1749-6632.2010.05554.x
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model
Jedd M. Hillegass (2010)
10.5694/mja11.10125
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen (2011)
10.18632/oncotarget.7229
Targeting hypoxic response for cancer therapy
E. Paolicchi (2016)
Simian virus 40: the link with human malignant mesothelioma is well established.
M. Carbone (2000)
10.1007/s13665-015-0106-8
Discovery of new biomarkers for malignant mesothelioma
J. Creaney (2015)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1093/carcin/bgv174
Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice
R. Pietrofesa (2016)
10.1002/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5
Primary human mesothelioma cells express class II MHC, ICAM‐1 and B7–2 and can present recall antigens to autologous blood lymphocytes
L. Mutti (1998)
10.1056/NEJMc1713444
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
M. Yarchoan (2017)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1186/s12014-016-9103-3
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
D. Morré (2016)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1038/cddis.2015.153
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
H. Yang (2015)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells.
A. Xu (1999)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1289/EHP.021101003
Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species.
A. Xu (2002)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1073/pnas.0803933105
The Nalp3 inflammasome is essential for the development of silicosis
Suzanne L. Cassel (2008)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1038/mt.2009.309
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.
D. Sterman (2010)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.5858/arpa.2011-0039-RA
Mesothelioma not associated with asbestos exposure.
B. Jasani (2012)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1200/JCO.2016.34.15_SUPPL.8519
Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy.
M. Zauderer (2016)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1097/MCP.0000000000000167
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
10.1038/nature01593
A role for Wnt signalling in self-renewal of haematopoietic stem cells
T. Reya (2003)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)



This paper is referenced by
Multimodality treatment of malignant pleural mesothelioma
Schil (2019)
10.1016/j.critrevonc.2020.102949
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review.
Tamkin Ahmadzada (2020)
10.1016/j.jtho.2020.03.025
Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?
M. Carbone (2020)
10.1080/14712598.2020.1703945
Nivolumab for the treatment of unresectable pleural mesothelioma
K. Hotta (2019)
10.1158/2159-8290.CD-19-1220
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
M. Carbone (2020)
10.1016/j.jtho.2018.11.006
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
M. Carbone (2019)
10.3390/cancers12082285
YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms
T. G. Johnson (2020)
10.1016/j.lungcan.2018.11.034
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Licun Wu (2019)
10.2217/fon-2020-0279
Making precision surgical strategies a reality: are we ready for a paradigm shift in thoracic surgical oncology?
M. Migliore (2020)
10.3390/cancers12082310
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
H. Yang (2020)
10.1177/1758835920971421
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
H. Yang (2020)
10.3389/fonc.2020.00388
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
C. Blanquart (2020)
10.1245/s10434-019-07357-0
How Old is Too Old to Operate for Mesothelioma?
DO JustinM.Karush (2019)
10.1016/j.jtho.2019.02.022
Progress in the Diagnosis and Treatment of Thoracic Malignancies Continues Unabated.
A. Adjei (2019)
10.21037/ATM.2020.03.58
Malignant pleural mesothelioma: between pragmatism and hope.
M. Migliore (2020)
10.1038/s41598-020-75807-x
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
Sabrina Borchert (2020)
10.1016/S1877-1203(18)30005-3
Quels résultats de l’immunothérapie dans les tumeurs thoraciques rares ?
N. Girard (2018)
10.1155/2019/4183157
HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
Y. Wang (2019)
10.1111/resp.13881
Pleural effusions and pneumothorax: Beyond simple plumbing: Expert opinions on knowledge gaps and essential next steps.
Rajesh Thomas (2020)
10.3390/cells8091091
Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
G. Vlacic (2019)
10.1136/jitc-2019-000461
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
K. Hotta (2020)
10.1016/j.ebiom.2020.103031
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Bill T V Duong (2020)
10.5772/INTECHOPEN.88783
Potential Roles of Matrix Metalloproteinases in Malignant Mesothelioma
Shibo Ying (2019)
10.3389/fcell.2019.00221
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma
T. G. Johnson (2019)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
10.12688/f1000research.15796.1
Multimodality treatment of malignant pleural mesothelioma
L. Berzenji (2018)
10.1016/j.lungcan.2020.05.023
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
K. Otsuka (2020)
10.12688/f1000research.15512.3
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort
W. Amin (2018)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1245/s10434-019-07357-0
How Old is Too Old to Operate for Mesothelioma?
J. Karush (2019)
10.1002/cncr.33145
Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin
R. Hassan (2020)
10.3389/fonc.2020.01413
gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma
E. Peerschke (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar